DrugPatentWatch Database Preview

Details for Patent: 7,754,702

« Back to Dashboard

Which drugs does patent 7,754,702 protect, and when does it expire?

Patent 7,754,702 protects INJECTAFER and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 7,754,702

Title:	Methods and compositions for administration of iron
Abstract:	The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
Inventor(s):	Helenek; Mary Jane (Brookville, NY), Tokars; Marc L. (Douglassville, PA), Lawrence; Richard P. (Calverton, NY)
Assignee:	Luitpold Pharmaceuticals, Inc. (Shirley, NY)
Application Number:	11/620,986
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,754,702
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery;

Drugs Protected by US Patent 7,754,702

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Am Regent	INJECTAFER	ferric carboxymaltose	INJECTABLE;INTRAVENOUS	203565-001	Jul 25, 2013		RX	Yes	Yes			Y			METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
Am Regent	INJECTAFER	ferric carboxymaltose	INJECTABLE;INTRAVENOUS	203565-001	Jul 25, 2013		RX	Yes	Yes			Y			METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
Am Regent	INJECTAFER	ferric carboxymaltose	INJECTABLE;INTRAVENOUS	203565-001	Jul 25, 2013		RX	Yes	Yes			Y			A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
Am Regent	INJECTAFER	ferric carboxymaltose	INJECTABLE;INTRAVENOUS	203565-001	Jul 25, 2013		RX	Yes	Yes			Y			A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON

International Family Members for US Patent 7,754,702

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007205167
Canada	2635894
Canada	2953964
China	101365458
Cyprus	1118780